Identifying Predictors of Anti-VEGF Treatment Response in Patients with Neovascular Age-Related Macular Degeneration through Discriminant and Principal Component Analysis

被引:5
|
作者
Holz, Frank G. [1 ]
Tadayoni, Ramin [3 ]
Beatty, Stephen [4 ]
Berger, Alan R. [5 ,6 ]
Cereda, Matteo G. [7 ]
Hykin, Philip [8 ]
Hoyng, Carel B. [10 ]
Wittrup-Jensen, Kim [2 ]
Altemark, Andreas [2 ]
Nilsson, Jonas [11 ]
Kim, Kun [12 ]
Sivaprasad, Sobha [8 ,9 ]
机构
[1] Univ Bonn, Dept Ophthalmol, Bonn, Germany
[2] Bayer Pharmaceut, Berlin, Germany
[3] Univ Paris 07, Hop Lariboisiere, AP HP, Dept Ophthalmol,Sorbonne Paris Cite, Paris, France
[4] Inst Eye Surg, Dept Ophthalmol, Waterford, Ireland
[5] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada
[6] St Michaels Hosp, Toronto, ON, Canada
[7] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Milan, Italy
[8] Moorfields Eye Hosp, NIHR Biomed Ctr Res Ophthalmol, London, England
[9] Kings Coll Hosp London, Dept Ophthalmol, London, England
[10] Radboud Univ Nijmegen Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands
[11] Real World Strategy & Analyt, Mapi Grp, Stockholm, Sweden
[12] AstraZeneca Nord Balt, Hlth Econ, Sodertalje, Sweden
关键词
AURA; Intravitreal ranibizumab; Neovascular age-related macular degeneration; INTRAVITREAL RANIBIZUMAB; VISUAL-ACUITY; OUTCOMES; LIFE; AMD;
D O I
10.1159/000449001
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: AURA was an observational study that monitored visual acuity outcomes following ranibizumab use in neovascular age-related macular degeneration patients over 2 years. The aim of this analysis was to identify factors that were predictive of visual acuity outcomes in AURA. Methods: The correlation between the baseline characteristics, the use of resources and the visual acuity outcomes in AURA was explored using principal component analysis (PCA) and partial least-squares-discriminant analysis (PLS-DA). The response variables analysed were mean change in visual acuity over 2 years (analysed via PCA) and no decline in visual acuity at 2 years compared with baseline (analysed via PLS-DA). Results: The AURA dataset comprised 2,227 patients and 132 variables. Using PCA and PLS-DA, we found that the number of ranibizumab injections, clinic and monitoring visits, number of optical coherence tomography scans and ophthalmoscopies correlated with a change in visual acuity at Years 1 and 2, and are therefore key drivers of treatment success. Conclusion: This is a novel approach to graphically explore relationships between multiple correlated covariates and outcomes in real-life ophthalmology studies. It identified a number of variables that are positively linked with treatment outcomes. (C) 2016 S. Karger AG, Basel
引用
收藏
页码:49 / 55
页数:7
相关论文
共 50 条
  • [22] ANTI-VEGF TREATMENT PATTERNS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS IN PORTUGAL: A NATIONAL AND REGIONAL LEVEL ANALYSIS
    Afonso-Silva, M.
    Rocha, J., V
    Marques, A.
    Macedo, A. F.
    Laires, P. A.
    Almeida, A. S.
    Fernandes, J.
    Santana, R.
    VALUE IN HEALTH, 2020, 23 : S541 - S541
  • [23] Predictive Biomarkers of Age-Related Macular Degeneration Response to Anti-VEGF Treatment
    Oca, Ana I.
    Perez-Sala, Alvaro
    Pariente, Ana
    Ochoa, Rodrigo
    Velilla, Sara
    Pelaez, Rafael
    Larrayoz, Ignacio M.
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (12):
  • [24] Bevacizumab (Avastin) conjugated microbubbles for anti-VEGF treatment of neovascular age-related macular degeneration
    Zhang, Leilei
    Xu, Jeff
    Huang, Jiwei
    Roberts, Cynthia
    Xu, Ronald
    OPHTHALMIC TECHNOLOGIES XX, 2010, 7550
  • [25] Association of a Variant in VWA3A with Response to Anti-VEGF Treatment in Neovascular Age-Related Macular Degeneration
    Grunin, Michelle
    Beykin, Gala
    Rahmani, Elior
    Schweiger, Regev
    Barel, Gal
    Levi, Shira
    Hayoun, Sarah
    Rinsky, Batya
    Ganiel, Michal
    Carmi, Shai
    Halperin, Eran
    Chowers, Itay
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [26] Development of Subretinal Fibrosis After Anti-VEGF Treatment in Neovascular Age-Related Macular Degeneration
    Hwang, John C.
    Del Priore, Lucian V.
    Freund, K. Bailey
    Chang, Stanley
    Iranmanesh, Reza
    OPHTHALMIC SURGERY LASERS & IMAGING, 2011, 42 (01) : 6 - 11
  • [27] Characterizing anti-VEGF treatment patterns for neovascular age-related macular degeneration in the United Kingdom
    Jain, Mishank
    Cantrell, Ronald
    Chidambaram, Jaya Devi
    Judge, Davneet
    Dodds, Melanie
    McGrory, Sarah
    Bailey, Clare
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [28] Treatment Patterns and Associated Costs of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration
    Kiss, Szilard
    Dugel, Pravin U.
    Wilson, Kathleen
    Huang, Alice
    Smith, David
    Varker, Helen
    Johnston, Stephen S.
    Turpcu, Adam
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [29] Anti-VEGF therapies for the treatment of age-related macular degeneration
    Gower, Emily W.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2012, 1 (06) : 485 - 488
  • [30] Anti-VEGF Refractory Neovascular Age-Related Macular Degeneration: The Effect of Adjunctive Spironolactone Treatment
    Mantel, Irmela
    Dirani, Ali
    Parvin, Parmis
    Fabro, Filippo
    Gryczka, Aurelia
    Behar-Cohen, Francine
    OPHTHALMOLOGICA, 2016, 236 : 1 - 2